This clinical trial is focused on studying a type of cancer known as colorectal cancer, specifically when it is located on the left side of the colon and cannot be surgically removed or has spread to other parts of the body. The study is particularly interested in cases where the cancer does not have certain genetic mutations, specifically KRAS, NRAS, and BRAF mutations. The trial will compare two different treatment approaches to see which is more effective as a first-line treatment for this type of cancer.
Participants in the study will receive one of two treatment combinations. The first group will receive a medication called Amivantamab along with chemotherapy drugs known as mFOLFOX6 or FOLFIRI. The second group will receive a medication called Cetuximab along with the same chemotherapy options, mFOLFOX6 or FOLFIRI. Amivantamab is given as a solution for injection under the skin, while Cetuximab is administered as a solution for infusion into a vein. Some participants may receive a placebo, which looks like the real treatment but does not contain the active medication.
The purpose of the study is to compare the effectiveness of these treatments in terms of how long they can prevent the cancer from getting worse. Participants will be randomly assigned to one of the treatment groups and will receive their assigned treatment over a period of time. The study will monitor the progress of the cancer using standard medical assessments to determine which treatment combination is more effective. The trial is expected to continue until 2028, with recruitment starting in 2025.
Belgium 
France 
Germany 
Hungary 
Italy 
Poland 
Spain 
Sweden 
The Netherlands 
